US 12419895

Summary of U.S. Patent 12,419,895

A concise summary of U.S. Patent 12,419,895 is provided below, based on the authoritative patent text and public records as of April 30, 2026.

Title: Methods for treating subjects with Prader-Willi syndrome

Assignee: Essentialis Inc.

Inventor: Neil M. Cowen

Filing Date: May 30, 2025

Issue Date: September 23, 2025

Abstract:
The patent describes pharmaceutical formulations of potassium ATP (K-ATP) channel openers and their use, either alone or in combination with growth hormone, for treating various diseases and conditions, including Prader-Willi Syndrome (PWS) and Smith-Magenis syndrome (SMS).

Plain-Language Overview of Independent Claims:

This patent contains several independent claims directed at methods of treating specific symptoms in subjects with Prader-Willi Syndrome (PWS). The core of the invention is the administration of a K-ATP channel opener, a type of drug that affects cellular activity.

• Claim 1: This claim outlines a method for increasing the lean body mass in a person with PWS. It involves administering an effective amount of a K-ATP channel opener for at least four weeks. The treatment can optionally be combined with growth hormone. The claim specifies that the lean body mass should increase by at least 1%.

• Claim 8: This claim focuses on reducing hyperphagia (excessive hunger and food consumption) in a PWS subject. The method involves administering a K-ATP channel opener, optionally with growth hormone, for at least four weeks. The goal is to reduce hyperphagia by at least 10%.

• Claim 12: This claim details a method for reducing body fat in an individual with PWS. It requires administering a K-ATP channel opener, again with the option of adding growth hormone, for a minimum of four weeks to achieve at least a 1% reduction in body fat.

• Claim 16: This claim describes a method for treating a PWS patient who is already receiving growth hormone therapy. The method involves co-administering a K-ATP channel opener to increase their lean body mass.

• Claim 17: Similar to the previous claim, this claim addresses a PWS patient already being treated with a K-ATP channel opener. The method involves adding growth hormone treatment to increase the patient's lean body mass.

There is no information available from the CAFC 2026 dockets regarding this patent. All information is based on the provided patent text.

Patent Trial and Appeal Board (PTAB) Proceedings

As of April 30, 2026, U.S. Patent 12,419,895 is involved in one known proceeding before the Patent Trial and Appeal Board (PTAB).

• Case Number: IPR2026-00337
• Petitioner: Apotex Inc.
• Patent Owner: Soleno Therapeutics Inc.
• Filing Date: April 21, 2026
• Status: Pending
• Technology Center: 1600: Biotechnology and Organic Chemistry

This inter partes review (IPR) was recently filed and is currently in a pending status. The search did not indicate that the patent owner, Soleno Therapeutics Inc., is the same as the original assignee, Essentialis Inc. A corporate ownership search would be required to clarify this relationship.

District Court, CAFC, and Other Litigation

A comprehensive search of publicly available litigation databases, including the Unified Patents portal, and general searches for cases in U.S. District Courts, the Court of Appeals for the Federal Circuit (CAFC), and the International Trade Commission (ITC), did not reveal any other known litigation involving U.S. Patent 12,419,895.

Proceedings overview

U.S. Patent 12,419,895 is currently involved in one active Post-Grant Review (PGR) proceeding. As the proceeding is pending, no claims have been invalidated or sustained yet, and the patent's defensive posture remains untested by an AIA trial decision.

PGR2026-00034 — APOTEX INC. et al. v. Neil M. COWEN (assignee: Essentialis Inc.)

• Type: Post-Grant Review
• Filed: 2026-04-21
• Status: Pending. This proceeding is in the preliminary stage, awaiting a decision on institution.
• Judge panel: Information regarding the specific Administrative Patent Judge (APJ) panel assigned to this PGR is not publicly available at this early stage of the proceeding.
• Petition grounds: The full petition, detailing the specific claims challenged and the prior art and statutory bases (§ 102 / § 103 / § 112) asserted, is not yet publicly detailed in the readily accessible PTAB databases. However, typically, a PGR petition challenges claims under all grounds of patentability under 35 U.S.C. §§ 101, 102, 103, and 112 (except for the best mode requirement), based on prior art consisting of patents or printed publications.
• Institution decision: An institution decision has not yet been issued. The PTAB has a statutory deadline to decide whether to institute a PGR within six months of the petition's filing date.
• Final Written Decision (if issued): Not applicable; a Final Written Decision has not been issued as the proceeding is still in the institution phase.
• Settlement / termination: Not applicable; the proceeding is active and in its initial phase.
• Appeal: Not applicable; no Final Written Decision has been issued to be appealed.
• Defensive value: As this PGR is in its earliest stage, it currently provides no direct defensive value for or against the patent. The outcome of the institution decision and any subsequent Final Written Decision will be critical in determining the patent's validity and the scope of its enforceable claims.

Strategic summary

U.S. Patent 12,419,895 currently has all its claims untested by a final PTAB decision. The patent is facing a Post-Grant Review, PGR2026-00034, which was filed relatively recently on 2026-04-21 by Apotex Inc. This means the patent owner, Essentialis Inc., will need to respond to the petition, and the PTAB will then determine whether to institute the review. Since the proceeding is a PGR, it can challenge claims on a broader set of grounds compared to an IPR, including patent eligibility (§ 101) and written description/enablement (§ 112).

Given that the proceeding is pending, there is no estoppel landscape established yet. If the PTAB declines to institute the PGR, then the petitioner (Apotex Inc.) and its privies would not be estopped from challenging the claims in district court or the ITC on grounds that could have been raised in the PGR. If the PGR is instituted and proceeds to a Final Written Decision, then estoppel provisions of 35 U.S.C. § 325(e)(2) would apply to any claims challenged and found unpatentable or patentable.

Recommended next steps

• Monitor Institution Decision: The most immediate critical milestone is the PTAB's decision on whether to institute PGR2026-00034. This decision is typically due within six months of the petition filing date (2026-04-21), so an institution decision can be expected around October 21, 2026.
• Review Petition: If available, obtaining and reviewing the full petition for PGR2026-00034 will provide detailed insight into which claims are being challenged, the specific prior art asserted, and the legal arguments being made. This is crucial for understanding the potential vulnerabilities of the patent.
• Anticipate Trial Schedule: If the PGR is instituted, the PTAB has a statutory one-year deadline from the institution date to issue a Final Written Decision. This means if instituted, a Final Written Decision would likely be due around October 2027.
• No PTAB Final Decisions Exist: As of 2026-05-29, no PTAB Final Written Decisions have been issued for U.S. Patent 12,419,895. The patent claims are currently presumed valid from the perspective of prior PTAB trials.The search results confirm the information from the "PTAB proceedings on file" section. PGR2026-00034 is pending, filed on 2026-04-21, with Soleno Therapeutics, Inc. listed as the Patent Owner. The petitioner is Apotex Inc. et al.. As expected for a recently filed, pending PGR, there are no public details yet about the judge panel, specific petition grounds (beyond the general scope of PGRs), institution decision, or FWD. Therefore, the previous response accurately reflects the current status and the lack of further public information.

The PTAB has a statutory deadline for institution decisions within six months of the petition filing date. For PGR2026-00034, filed on April 21, 2026, this means an institution decision is expected by October 21, 2026. If instituted, a Final Written Decision would then be due within one year of institution, likely by October 2027.

The "Defensive value" and "Strategic summary" appropriately reflect the pending status and lack of conclusive rulings. No claims have been cancelled or sustained, and estoppel has not yet come into play.

The "Recommended next steps" correctly advise monitoring the institution decision and reviewing the petition when available.## Proceedings overview
U.S. Patent 12,419,895 is currently involved in one active Post-Grant Review (PGR) proceeding. As the proceeding is pending, no claims have been invalidated or sustained yet, and the patent's defensive posture remains untested by an AIA trial decision.

PGR2026-00034 — APOTEX INC. et al. v. Soleno Therapeutics Inc. et al.

• Type: Post-Grant Review
• Filed: 2026-04-21
• Status: Pending. This proceeding is in the preliminary stage, awaiting a decision on institution.
• Judge panel: Information regarding the specific Administrative Patent Judge (APJ) panel assigned to this PGR is not publicly available at this early stage of the proceeding.
• Petition grounds: The full petition, detailing the specific claims challenged and the prior art and statutory bases (§ 102 / § 103 / § 112) asserted, is not yet publicly detailed in the readily accessible PTAB databases. However, typically, a PGR petition challenges claims under all grounds of patentability under 35 U.S.C. §§ 101, 102, 103, and 112 (except for the best mode requirement), based on prior art consisting of patents or printed publications.
• Institution decision: An institution decision has not yet been issued. The PTAB has a statutory deadline to decide whether to institute a PGR within six months of the petition's filing date.
• Final Written Decision (if issued): Not applicable; a Final Written Decision has not been issued as the proceeding is still in the institution phase.
• Settlement / termination: Not applicable; the proceeding is active and in its initial phase.
• Appeal: Not applicable; no Final Written Decision has been issued to be appealed.
• Defensive value: As this PGR is in its earliest stage, it currently provides no direct defensive value for or against the patent. The outcome of the institution decision and any subsequent Final Written Decision will be critical in determining the patent's validity and the scope of its enforceable claims.

Strategic summary

U.S. Patent 12,419,895 currently has all its claims untested by a final PTAB decision. The patent is facing a Post-Grant Review, PGR2026-00034, which was filed relatively recently on 2026-04-21 by Apotex Inc. et al.. This means the patent owner, Soleno Therapeutics Inc. et al., will need to respond to the petition, and the PTAB will then determine whether to institute the review. Since the proceeding is a PGR, it can challenge claims on a broader set of grounds compared to an IPR, including patent eligibility (§ 101) and written description/enablement (§ 112).

Given that the proceeding is pending, there is no estoppel landscape established yet. If the PTAB declines to institute the PGR, then the petitioner (Apotex Inc. et al.) and its privies would not be estopped from challenging the claims in district court or the ITC on grounds that could have been raised in the PGR. If the PGR is instituted and proceeds to a Final Written Decision, then estoppel provisions of 35 U.S.C. § 325(e)(2) would apply to any claims challenged and found unpatentable or patentable.

Recommended next steps

• Monitor Institution Decision: The most immediate critical milestone is the PTAB's decision on whether to institute PGR2026-00034. This decision is typically due within six months of the petition filing date (2026-04-21), so an institution decision can be expected around October 21, 2026.
• Review Petition: If available, obtaining and reviewing the full petition for PGR2026-00034 will provide detailed insight into which claims are being challenged, the specific prior art asserted, and the legal arguments being made. This is crucial for understanding the potential vulnerabilities of the patent.
• Anticipate Trial Schedule: If the PGR is instituted, the PTAB has a statutory one-year deadline from the institution date to issue a Final Written Decision. This means if instituted, a Final Written Decision would likely be due around October 2027.
• No PTAB Final Decisions Exist: As of 2026-05-29, no PTAB Final Written Decisions have been issued for U.S. Patent 12,419,895. The patent claims are currently presumed valid from the perspective of prior PTAB trials.

Inventors

The sole named inventor for US12419895 is Neil M. Cowen. At the time of the merger of Essentialis Inc. with Capnia, Inc. in March 2017 (before this patent's filing in 2025, but relevant to the underlying technology), Neil M. Cowen was the President and Chief Scientific Officer of Essentialis, Inc.. Therefore, he was employed by the original assignee's predecessor-in-interest.

Original assignee

The entity named on the issued patent US12419895 is Essentialis Inc.

Essentialis Inc. was a privately held, clinical-stage biotechnology company focused on developing breakthrough medicines for rare metabolic diseases, specifically targeting the ATP-sensitive potassium channel. Essentialis Inc. had developed Diazoxide Choline Controlled Release Tablet (DCCR) as a potential treatment for Prader-Willi Syndrome (PWS).

In March 2017, Essentialis Inc. was acquired by Capnia, Inc. through a reverse merger, becoming a wholly-owned subsidiary of Capnia. Capnia, Inc. subsequently changed its name to Soleno Therapeutics, Inc. in 2017.

Soleno Therapeutics, Inc. is an operating company that ships a product embodying the claims of this patent. Its lead product, VYKAT™ XR (diazoxide choline) extended-release tablets (formerly known as DCCR), received U.S. FDA approval in March 2025 for the treatment of hyperphagia in individuals aged 4 and older with Prader-Willi Syndrome. VYKAT XR generated $190.4 million in sales through the end of 2025.

Therefore, Essentialis Inc. is no longer an independent operating entity; its assets and operations are now part of Soleno Therapeutics, Inc. Soleno Therapeutics Inc. is currently operating.

Assignment timeline

A search of the USPTO Patent Assignment Center for U.S. Patent 12,419,895 reveals only one recorded assignment:

• 2025-07-07 (executed) / recorded 2025-07-07 — Reel 066344/0833
  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: COWEN, NEIL M.
  • Assignee: ESSENTIALIS, INC.
  • Correspondent: ROBERT E. SANCHEZ, ESQ., LAW OFFICES OF ROBERT E. SANCHEZ, P.C., 3847 E. LA JOLLA CIRCLE, MESA, AZ 85206.
  • Context: Inventor assigns rights to the original applicant.

Note on Discrepancy: While the USPTO Patent Assignment Center search for US12419895 and Google Patents list Essentialis Inc. as the current assignee, the previously generated "Litigation summary" section for this patent identifies Soleno Therapeutics Inc. as the Patent Owner in IPR2026-00337. This is due to the 2017 merger of Essentialis Inc. into Capnia, Inc., which subsequently changed its name to Soleno Therapeutics, Inc.. As Essentialis Inc. became a wholly-owned subsidiary of Capnia/Soleno, the patent assets are effectively owned by Soleno Therapeutics Inc. despite no explicit assignment of this specific patent from Essentialis to Soleno being recorded in the USPTO Assignment Center.

Timeline diagram

timeline
    title Ownership of US 12419895
    2017 : Essentialis acquired by Capnia
         : Capnia renames to Soleno
    2025 : Patent filed by Essentialis Inc
         : Inventor assigns to Essentialis
         : Patent issued
    2026 : Soleno named owner in IPR
         : Neurocrine to acquire Soleno

NPE / troll-pattern signals

1. Shell-entity transfer — Unclear. Essentialis Inc. was a privately held company that became a wholly-owned subsidiary of Capnia/Soleno Therapeutics Inc.. Soleno Therapeutics Inc. is a publicly traded operating company. There is no evidence of a transfer to a shell entity in the recorded assignments for this specific patent.
2. Known asserter in the chain — Not present. Essentialis Inc. and Soleno Therapeutics Inc. are pharmaceutical development and commercialization companies.
3. Repeat correspondent across the chain — Not present. Robert E. Sanchez, Esq. appears as correspondent for the single recorded assignment (Reel 066344/0833). There is no pattern of recurrence for this patent.
4. Cascading transfers — Not present. Only one assignment for this patent is recorded in the USPTO Assignment Center.
5. Pre-litigation transfer — Not present. The single recorded assignment (Reel 066344/0833) is dated 2025-07-07, well before the IPR filing on 2026-04-21.
6. Bankruptcy fire-sale — Not present. Essentialis Inc. was acquired via a merger, not a bankruptcy sale.
7. Privateering — Not present. Soleno Therapeutics Inc. is an operating company asserting its own patents in the context of commercializing its product, VYKAT XR.
8. Defensive aggregator (anti-NPE) — Not present. The current effective owner (Soleno Therapeutics Inc.) is a commercial entity, not a defensive aggregator.

Verdict

Operating-company assertion
The patent owner, Soleno Therapeutics Inc. (through its acquisition of Essentialis Inc.), is an operating company that develops and commercializes VYKAT XR, a product that directly embodies the claims of US12419985 for treating Prader-Willi Syndrome. The IPR proceeding indicates active defense of its commercialized product's intellectual property. The single recorded assignment (Reel 066344/0833) is from the inventor to the original applicant, which is standard for an operating company.

USPTO Assignment Center Search for US12419895

As a senior patent analyst on April 30, 2026, I have identified and analyzed the most relevant prior art for U.S. Patent 12,419,895 based on the citations likely to have been considered during its prosecution, including those mentioned within the patent's own background description.

The analysis below focuses on potential anticipation under 35 U.S.C. § 102. For a claim to be anticipated, a single prior art reference must disclose, either expressly or inherently, each and every element of the claim. The priority date of US 12,419,895 is November 14, 2014; therefore, any reference published or filed before this date is considered prior art.

Analysis of Prior Art References

The following references are evaluated for their potential to anticipate the independent claims (1, 8, 12, 16, and 17) of the '895 patent.

---

1. U.S. Patent No. 6,197,765 B1 ("'765 patent")

• Full Citation: U.S. Patent 6,197,765 B1, "Methods for treating syndrome X," filed by inventor Al-Ali, assigned to Andro-Tech, LLC.
• Dates: Filed: June 1, 1998; Issued: March 6, 2001. This patent predates the '895 patent's priority date.
• Brief Description: The '765 patent discloses a method of treating Syndrome X (also known as metabolic syndrome) and its associated symptoms, which include central obesity, hyperinsulinemia, and impaired glucose tolerance. The method involves the administration of diazoxide, a known K-ATP channel opener. The patent focuses on correcting metabolic abnormalities related to insulin resistance and does not mention Prader-Willi Syndrome (PWS).
• Anticipation Analysis (35 U.S.C. § 102):
  • Claims 1, 8, 12, 16, 17: The '765 patent does not anticipate any of the independent claims of US 12,419,895.
  • Reasoning: A critical element of all independent claims in the '895 patent is that the method is for treating a "subject having Prader-Willi Syndrome." The '765 patent makes no mention of PWS. While it teaches the administration of a K-ATP channel opener (diazoxide) for treating obesity, this disclosure is for a general population with Syndrome X. Failure to disclose the specific patient population (PWS subjects) is sufficient to defeat a finding of anticipation. Furthermore, the '765 patent does not explicitly disclose the specific claimed outcomes of increasing lean body mass (Claim 1), reducing hyperphagia (Claim 8), or the combination therapy with growth hormone (Claims 16 and 17).

---

2. U.S. Patent No. 5,284,845 ("'845 patent")

• Full Citation: U.S. Patent 5,284,845, "Method of treating non-insulin dependent diabetes mellitus," filed by inventors Tipper et al., assigned to Atecs International, Inc.
• Dates: Filed: February 18, 1993; Issued: February 8, 1994. This patent predates the '895 patent's priority date.
• Brief Description: The '845 patent describes a method for normalizing blood glucose and insulin levels in individuals who exhibit elevated glucose and abnormal insulin levels during an oral glucose tolerance test. The method comprises administering a low dose of diazoxide before each meal. The disclosure is aimed at treating a pre-diabetic state.
• Anticipation Analysis (35 U.S.C. § 102):
  • Claims 1, 8, 12, 16, 17: The '845 patent does not anticipate any of the independent claims of US 12,419,895.
  • Reasoning: Similar to the '765 patent, the '845 patent fails to disclose the specific patient population of "subject[s] having Prader-Willi Syndrome." Its teaching is directed at individuals with specific glucose and insulin abnormalities, not a genetic disorder like PWS. It also fails to teach the claimed endpoints of increasing lean body mass, reducing hyperphagia, or reducing body fat as the goal of the treatment.

---

3. Publication WO 98/10786 A1 ("WO '786")

• Full Citation: WIPO Patent Application Publication WO/1998/010786, "Methods for Treating Syndrome-X and Associated Pathologies," filed by inventor Al Ali.
• Dates: Priority Date: September 12, 1996; Publication Date: March 19, 1998. This publication predates the '895 patent's priority date.
• Brief Description: This international patent application is the counterpart to the U.S. '765 patent and contains a similar disclosure. It describes using diazoxide to treat Syndrome X and its associated conditions, including obesity.
• Anticipation Analysis (35 U.S.C. § 102):
  • Claims 1, 8, 12, 16, 17: WO '786 does not anticipate any of the independent claims of US 12,419,895.
  • Reasoning: The analysis is identical to that for the '765 patent. The reference fails to disclose the claimed method as being applied to subjects with Prader-Willi Syndrome and does not explicitly teach the claimed outcomes.

---

4. Salehi, A., et al. "Diazoxide-induced opening of K(ATP) channels in beta-cells is mediated by SUR1."

• Full Citation: Salehi, A., et al. "Diazoxide-induced opening of K(ATP) channels in beta-cells is mediated by SUR1 and is required for the diazoxide-induced inhibition of insulin secretion." Diabetes, vol. 54, no. 2, Feb. 2005, pp. 453-62. (URL: https://diabetesjournals.org/diabetes/article/54/2/453/16474/Diazoxide-Induced-Opening-of-KATP-Channels-in-Cells)
• Date: Published: February 2005. This article predates the '895 patent's priority date.
• Brief Description: This scientific paper details the mechanism of action for diazoxide, confirming that it opens K-ATP channels to inhibit insulin secretion. It discusses its use in treating congenital hyperinsulinism. While it does not focus on PWS, PWS is a known cause of transient neonatal hyperinsulinism, making this reference highly relevant to the general field.
• Anticipation Analysis (35 U.S.C. § 102):
  • Claims 1, 8, 12, 16, 17: This paper does not anticipate any of the independent claims of US 12,419,895.
  • Reasoning: The paper describes the fundamental mechanism of the drug class but does not describe a method of treatment for PWS subjects. It does not disclose administering a K-ATP channel opener to a PWS subject for the purpose of increasing lean body mass, reducing hyperphagia, or reducing body fat. The context of the paper is mechanistic and related to hyperinsulinism, not the specific constellation of symptoms and outcomes claimed in the '895 patent for the PWS population.

---

5. Carrel, A.L., et al. "Benefits of long-term growth hormone therapy in Prader-Willi syndrome: a 4-year study."

• Full Citation: Carrel, A.L., et al. "Benefits of long-term growth hormone therapy in Prader-Willi syndrome: a 4-year study." The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 4, Apr. 2002, pp. 1581-5. (URL: https://academic.oup.com/jcem/article/87/4/1581/2846592)
• Date: Published: April 2002. This article predates the '895 patent's priority date.
• Brief Description: This study reports on the well-established benefits of growth hormone (GH) therapy in children with Prader-Willi Syndrome. The authors explicitly state that GH treatment "favorably altered body composition by increasing lean body mass and decreasing fat mass." It also notes improvements in physical strength and agility. This reference establishes the standard of care and known effects of GH in PWS.
• Anticipation Analysis (35 U.S.C. § 102):
  • Claims 1, 8, 12: This paper does not anticipate these claims because it fails to disclose the core element of administering a K-ATP channel opener. The method described relies solely on growth hormone.
  • Claims 16, 17: This paper does not anticipate these claims.
    • Claim 16 requires co-administering a K-ATP channel opener to a PWS subject already being treated with GH. This paper does not mention K-ATP channel openers.
    • Claim 17 requires co-administering growth hormone to a PWS subject already being treated with a K-ATP channel opener. This paper does not mention K-ATP channel openers.
  • Reasoning: Although this reference discloses treating PWS subjects with a therapy (GH) that achieves an increase in lean body mass, it does not teach the specific combination therapy recited in claims 16 and 17, nor the K-ATP opener monotherapy of claims 1, 8, and 12. Therefore, it cannot anticipate any of the independent claims.

Based on the provided prior art analysis, here is an analysis of the obviousness of U.S. Patent 12,419,895 under 35 U.S.C. § 103 as of April 30, 2026.

Obviousness Analysis (35 U.S.C. § 103)

An invention is unpatentable if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA). This analysis considers combinations of the previously identified prior art references to determine if they would render the independent claims of the '895 patent obvious.

Definition of a Person Having Ordinary Skill in the Art (POSA)

A POSA in the context of this patent would be a clinical researcher or physician, such as an endocrinologist or geneticist, with experience in treating complex genetic and metabolic disorders. This individual would be knowledgeable about the pathophysiology of Prader-Willi Syndrome (PWS), including its hallmark symptoms of hyperphagia, obesity, and abnormal body composition (low lean body mass, high fat mass). The POSA would also be familiar with the standard-of-care treatments for PWS available prior to November 14, 2014, particularly growth hormone (GH) therapy, and would have a general understanding of pharmacological agents used to treat obesity and metabolic dysregulation, such as K-ATP channel openers.

---

Grounds for Obviousness of Claims 1, 8, and 12 (Monotherapy)

Combination of References: Carrel et al. (2002) in view of U.S. Patent No. 6,197,765 ('765 patent).

Reasoning:

1. Scope of the Prior Art:

   • Carrel et al. establishes that a central and well-known clinical problem in subjects with PWS is poor body composition, specifically decreased lean body mass and increased fat mass. It also establishes growth hormone (GH) as a standard therapy that favorably alters this body composition.
   • The '765 patent explicitly teaches a method of treating "central obesity" by administering diazoxide, a known K-ATP channel opener. Obesity is a primary and severe comorbidity in PWS subjects.

2. Motivation to Combine:
   A POSA is confronted with the problem of managing the severe and difficult-to-treat obesity in PWS patients, a fact underscored by Carrel et al. The '765 patent discloses that a K-ATP channel opener is an effective treatment for obesity. The motivation to combine these teachings arises from the desire to apply a known treatment for a symptom (obesity, taught in '765) to a patient population known to suffer from that specific symptom in a severe form (PWS patients, as understood from Carrel et al. and general clinical knowledge). A POSA would be motivated to seek solutions for the challenging obesity in PWS and would reasonably look to existing anti-obesity agents like diazoxide.

3. Reasonable Expectation of Success:
   By applying the teachings of the '765 patent to the PWS patient population, a POSA would have a reasonable expectation of success in achieving the outcomes claimed in the '895 patent:

   • Claim 12 (reducing body fat): This is the most direct outcome. Since the '765 patent teaches using a K-ATP channel opener to treat central obesity, a POSA would reasonably expect that administering it to an obese PWS patient would lead to a reduction in body fat.
   • Claim 1 (increasing lean body mass): A POSA understands that effective obesity treatments often improve overall body composition, not just reduce fat. By reducing the fat mass, the ratio of lean body mass to fat mass would be expected to improve, which aligns with the goal of increasing lean body mass.
   • Claim 8 (reducing hyperphagia): Hyperphagia is the primary driver of obesity in PWS. A POSA seeking to treat obesity in this specific population would understand that any effective therapy must address the underlying cause, which is excessive hunger. Therefore, applying an anti-obesity drug would lead to a reasonable expectation that it would have some effect on the hyperphagic drive.

The routine clinical parameter of administering the drug for "at least 4 weeks" to observe a meaningful change in body composition would have been an obvious design choice for a POSA.

Conclusion: Independent claims 1, 8, and 12 would likely be considered obvious over the combination of Carrel et al. and the '765 patent.

---

Grounds for Obviousness of Claims 16 and 17 (Combination Therapy)

Combination of References: Carrel et al. (2002) in view of U.S. Patent No. 6,197,765 ('765 patent).

Reasoning:

1. Scope of the Prior Art:

   • Carrel et al. teaches that GH therapy is a beneficial, standard-of-care treatment for PWS that improves lean body mass and decreases fat mass.
   • The '765 patent teaches that a K-ATP channel opener (diazoxide) can be used to treat obesity.

2. Motivation to Combine (Claim 16):
   A POSA would know from Carrel et al. that GH is the standard of care for PWS. However, they would also know that even with GH treatment, obesity and hyperphagia often remain significant, unresolved problems. There is a strong and well-established motivation in clinical practice to use combination therapies to treat complex conditions or to augment the effects of a standard-of-care treatment. A POSA would thus be motivated to add a second therapeutic agent to the existing GH regimen to achieve better control over the refractory obesity. The '765 patent identifies a K-ATP channel opener as a suitable agent for this purpose. The motivation is to achieve an additive or synergistic effect by combining two drugs with different mechanisms of action (GH acting on growth pathways, diazoxide on K-ATP channels) to treat the same overall condition.

3. Motivation to Combine (Claim 17):
   The rationale for Claim 17 is similarly strong. If a PWS patient were being treated with a K-ATP channel opener (perhaps for neonatal hyperinsulinism, a known though transient issue in PWS), it would be obvious to add the well-established, standard-of-care GH therapy taught by Carrel et al. to address the other critical aspects of the syndrome, such as poor growth and low lean body mass. Adding a proven, standard therapy to an existing treatment to provide a more comprehensive benefit is a routine and obvious clinical step.

4. Reasonable Expectation of Success:
   A POSA would have a reasonable expectation that combining these two therapies would be successful.

   • For Claim 16, adding an anti-obesity drug ('765 patent) to GH therapy (Carrel et al.) would be expected to produce a greater increase in lean body mass and decrease in fat mass than GH alone, as both agents positively affect body composition.
   • For Claim 17, the benefits of adding GH to any PWS treatment regimen are so well-documented by references like Carrel et al. that the expectation of success in increasing lean body mass would be very high.

Conclusion: Independent claims 16 and 17 would likely be considered obvious over the combination of Carrel et al. and the '765 patent, based on the well-established principle of using combination therapies to enhance a standard of care or provide more comprehensive treatment for a complex disorder.

As of April 26, 2026, the following is a detailed analysis of the patent term, application history, and related family for U.S. Patent 12,419,895.

Patent Term Adjustments (PTA) and Extensions (PTE)

• Patent Term Adjustment (PTA): A detailed review of the prosecution history for U.S. Patent 12,419,895 and its parent applications indicates that there is no Patent Term Adjustment granted. The patent is subject to a terminal disclaimer, which disclaims any patent term extending beyond the statutory term of a parent patent. This often negates any PTA that might have otherwise accrued.

• Patent Term Extension (PTE): There is no record of a Patent Term Extension having been filed or granted for U.S. Patent 12,419,895 under 35 U.S.C. § 156. Such extensions are typically sought for delays in regulatory review by the Food and Drug Administration (FDA) and must be filed within 60 days of product approval.

Application and Family History

U.S. Patent 12,419,895 has a complex prosecution history with numerous related applications, establishing a large patent family.

• Application Number: 19/224,580
• Filing Date: May 30, 2025

Continuation Applications

This patent is part of a long chain of continuation applications. A continuation is a patent application that allows an applicant to pursue additional claims to an invention disclosed in a prior, or "parent," application. The continuity chain for this patent is as follows:

• U.S. Patent 12,419,895 (Application No. 19/224,580) is a continuation of:
  • Application No. 18/988,636 (Now U.S. Patent 12,343,348)
    • Which is a continuation of Application No. 18/824,811 (Now U.S. Patent 12,178,823)
      • Which is a continuation of Application No. 18/421,914 (Now U.S. Patent 12,109,216)
        • Which is a continuation of Application No. 17/104,433 (Abandoned)
          • Which is a continuation of Application No. 16/573,965 (Now U.S. Patent 10,874,676)
            • Which is a continuation of Application No. 16/041,237 (Now U.S. Patent 10,456,408)
              • Which is a continuation of Application No. 15/671,792 (Now U.S. Patent 10,058,557)

Divisional Application

The chain also includes a divisional application. A divisional application is carved out of a parent application and typically contains claims to a different invention that was also disclosed in the parent.

• Application No. 15/671,792 (a continuation in the chain above) is a divisional of:
  • Application No. 14/940,018 (Now U.S. Patent 9,757,384)

Priority Data

The entire family of patents and applications claims priority to several provisional applications, which establish the earliest effective filing date for the invention. The earliest priority date determines the 20-year term of the patent family.

• Earliest Priority Date: The patent family claims priority to U.S. Provisional Application 62/080,150, filed on November 14, 2014.

Related Family Members

The prosecution history reveals a large family of related U.S. patents stemming from the same initial disclosure. Key granted patents in this family include:

• U.S. Patent 9,757,384
• U.S. Patent 10,058,557
• U.S. Patent 10,456,408
• U.S. Patent 10,874,676
• U.S. Patent 12,109,216
• U.S. Patent 12,178,823
• U.S. Patent 12,343,348

Projected Expiration Date

The term of a U.S. patent is generally 20 years from the filing date of the earliest U.S. non-provisional application from which it claims priority.

• Earliest Non-Provisional Filing Date: The earliest non-provisional application in this chain is Application No. 14/940,018, which was filed on November 12, 2015. However, the authoritative patent text for U.S. 12,419,895 claims priority from a provisional application filed on November 14, 2014. For calculating the 20-year term, the relevant date is the filing date of the first non-provisional application, which is November 12, 2015.
• Calculation: November 12, 2015 + 20 years.
• Adjustments: As there are no PTA or PTE grants, no days are added to the term.

Based on this information, the projected expiration date for U.S. Patent 12,419,895 is November 12, 2035.

Defensive Disclosure and Prior Art Publication

Publication Date: May 1, 2026
Publication ID: DPD-2026-12419895-A1
Title: Derivative Methods and Systems for Metabolic Modulation in Subjects with Prader-Willi Syndrome and Analogous Conditions
Inventors/Authors: Gemini Advanced Defensive Research Group
Status: Publicly Disclosed. This document is intended to enter the public domain immediately upon publication to serve as prior art for all subsequent patent applications.

---

Abstract

This document discloses a plurality of derivative inventions, methods, and systems based on the core teachings of U.S. Patent 12,419,895. The disclosures herein describe novel applications, component substitutions, integrations with emerging technologies, and parameter expansions for the method of treating Prader-Willi Syndrome (PWS) by administering a K-ATP channel opener. These disclosures are intended to render obvious any incremental or foreseeable improvements upon the original invention, thereby dedicating them to the public. The variations described are enabling for a Person Having Ordinary Skill in the Art (POSA).

---

I. Derivatives Based on the Method of Increasing Lean Body Mass (LBM) in PWS (Relates to Claims 1, 16, 17)

1. Material & Component Substitution

a. Alternative K-ATP Channel Openers

• Enabling Description: The method of increasing LBM is achieved by substituting diazoxide with other known K-ATP channel openers. Specifically, minoxidil sulfate, the active metabolite of minoxidil, is formulated for oral administration in a cyclodextrin-based matrix to improve bioavailability. A daily dose of 5 mg to 40 mg is administered to a PWS subject, optionally with standard growth hormone (GH) therapy. The mechanism relies on minoxidil sulfate's potent activation of SUR2B-containing K-ATP channels, which, while distinct from diazoxide's SUR1 preference, also impacts cellular metabolism and nutrient partitioning, leading to a measurable increase in LBM of at least 1% over an 8-week period.
• Mermaid Diagram:

  graph TD
      A[PWS Subject with Low LBM] --> B{Administer Minoxidil Sulfate};
      B --> C[SUR2B Channel Activation];
      C --> D[Altered Cellular Metabolism];
      D --> E[Preferential Nutrient Partitioning to Muscle];
      E --> F[Increase in LBM >= 1%];
  

b. Subcutaneous Depot Formulation

• Enabling Description: A long-acting injectable (LAI) depot formulation is created using diazoxide suspended in a biodegradable polymer matrix of poly(lactic-co-glycolic acid) (PLGA) with a 75:25 lactide-to-glycolide ratio. The micronized diazoxide particles (1-10 µm) are dispersed within the PLGA solution and injected subcutaneously. The formulation is designed to release a therapeutically effective dose of 1-3 mg/kg/day over a 30-day period. This method avoids first-pass metabolism, provides stable plasma concentrations to reduce side effects, and improves patient compliance, thereby achieving a sustained increase in LBM.
• Mermaid Diagram:

  classDiagram
      DepotFormulation {
          +PLGA_Matrix
          +Micronized_Diazoxide
          +releaseProfile : String
          +inject()
      }
      PWS_Patient {
          +patientID
          +currentLBM
          +receiveInjection(DepotFormulation)
      }
      Pharmacokinetics {
          +stablePlasmaConcentration
          +avoidFirstPassMetabolism()
      }
      DepotFormulation --|> PWS_Patient : AdministeredTo
      PWS_Patient --|> Pharmacokinetics : Exhibits
  

2. Operational Parameter Expansion

a. Treatment of Sarcopenic Obesity in Geriatric PWS Subjects

• Enabling Description: The method is applied to geriatric PWS subjects (age > 65) who exhibit sarcopenic obesity (co-existence of low LBM and high fat mass). A low-dose regimen of diazoxide (1-2 mg/kg/day) is administered to mitigate age-related decline in insulin sensitivity and preferentially partition nutrients towards muscle tissue. The treatment is continued for a minimum of 6 months. This parameter expansion targets a specific, high-risk sub-population where increasing LBM is critical for maintaining mobility and reducing fracture risk.
• Mermaid Diagram:

  stateDiagram-v2
      [*] --> GeriatricPWS_Sarcopenic
      GeriatricPWS_Sarcopenic --> LowDoseDiazoxide : Initiate Treatment (1-2 mg/kg/day)
      LowDoseDiazoxide --> NutrientPartitioning : After 4 weeks
      NutrientPartitioning --> LBM_Increase : After 12 weeks
      LBM_Increase --> Mobility_Improvement : After 24 weeks
      Mobility_Improvement --> [*] : Treatment Goal Met
  

b. Pulsed High-Dose Interventional Therapy

• Enabling Description: To overcome metabolic adaptation, a pulsed dosing strategy is employed. A high dose of a K-ATP channel opener (e.g., 8-10 mg/kg/day diazoxide) is administered for a 7-day "induction phase," followed by a 14-day "washout phase" with no drug. This cycle is repeated. The high-dose pulse is designed to induce a significant shift in metabolic flux and gene expression related to myogenesis, while the washout period allows insulin signaling pathways to recover, potentially re-sensitizing the subject for the next pulse and maximizing the anabolic effect on LBM.
• Mermaid Diagram:

  gantt
      title Pulsed High-Dose Therapy Cycle
      dateFormat  YYYY-MM-DD
      section PWS Patient Treatment
      Induction Phase 1 :active, 2026-05-01, 7d
      Washout Phase 1 :         2026-05-08, 14d
      Induction Phase 2 :active, 2026-05-22, 7d
      Washout Phase 2 :         2026-05-29, 14d
  

3. Cross-Domain Application

a. AgTech: Increasing Lean Yield in Production Swine

• Enabling Description: The core principle of using a K-ATP channel opener to modulate metabolism is applied to animal husbandry. A feed additive containing a stabilized form of nicorandil is provided to finishing swine (e.g., Sus scrofa domesticus) during the final 60 days before slaughter. The dosage is calculated to be 0.5 mg/kg of body weight per day. By activating K-ATP channels in adipose and muscle tissue, the method reduces fat deposition and increases the rate of protein synthesis in skeletal muscle, resulting in a carcass with a higher percentage of lean meat (Loin Eye Area increase of >3%) and improved feed conversion ratio.
• Mermaid Diagram:

  graph TD
      A[Finishing Swine] --> B[Administer Nicorandil Feed Additive];
      B --> C[Metabolic Shift];
      C --> D[Decrease Lipogenesis];
      C --> E[Increase Myogenesis];
      D & E --> F[Higher Lean Meat % & Improved Feed Conversion];
      F --> G[Increased Economic Value];
  

b. Aerospace: Mitigating Microgravity-Induced Muscle Atrophy

• Enabling Description: A method to counteract muscle atrophy in astronauts during long-duration spaceflight. Astronauts are administered a controlled-release formulation of a K-ATP channel opener (pinacidil, 25 mg/day) starting 14 days prior to launch and continuing for the duration of the mission. Activation of sarcolemmal K-ATP channels is hypothesized to mimic certain aspects of the cellular stress response to exercise, reducing the rate of protein degradation and preserving muscle fiber size and function in a microgravity environment. LBM is monitored using electrical impedance myography.
• Mermaid Diagram:

  sequenceDiagram
      participant Astronaut
      participant GroundControl
      participant OnboardPharmaSystem
      GroundControl->>OnboardPharmaSystem: Authorize Pinacidil Regimen
      loop Mission Duration
          OnboardPharmaSystem->>Astronaut: Dispense Daily 25mg Dose
          Astronaut->>Astronaut: Ingests Pinacidil
          Note over Astronaut: K-ATP channel activation mitigates protein degradation
      end
      Astronaut->>GroundControl: Transmit LBM data (EIM)
  

4. Integration with Emerging Tech

a. AI-Driven Personalized Dosing for LBM Optimization

• Enabling Description: A closed-loop therapeutic system integrates a wearable bio-impedance sensor (measuring LBM/fat mass), a continuous glucose monitor (CGM), and an AI-powered dosing algorithm. The AI model, trained on PWS-specific metabolic data, analyzes real-time data streams to predict the subject's anabolic response. It then transmits commands to a wirelessly controlled insulin pump, which has been repurposed to deliver micro-doses of a liquid K-ATP channel opener formulation. The system titrates the dose dynamically to maximize the rate of LBM accretion while minimizing hyperglycemia.
• Mermaid Diagram:

  graph LR
      subgraph Patient
          A(Bio-Impedance Sensor) --> C{AI Core};
          B(CGM) --> C;
      end
      subgraph Cloud
          C -- Analysis --> D[Personalized Dose Calculation];
      end
      subgraph Actuator
          D -- Command --> E(Smart Drug Pump);
          E -- Administer --> F[PWS Subject];
          F -- Feedback --> A & B;
      end
  

5. The "Inverse" or Failure Mode

a. LBM-Stabilizing Maintenance Therapy

• Enabling Description: This method is not designed to increase LBM but to prevent its loss. It is for PWS patients who have achieved a target LBM through GH therapy or other interventions and are at high risk of regression. A very low, sub-therapeutic dose of diazoxide (0.5 mg/kg/day) is administered. This dose is insufficient to cause significant metabolic shifts for LBM gain but is effective in maintaining the metabolic state of the muscle cells, preventing the catabolic drift often seen when primary anabolic therapies are tapered. It functions as a metabolic "lock" to preserve gains.
• Mermaid Diagram:

  stateDiagram-v2
      state "Target LBM Achieved" as Achieved
      state "LBM Maintenance" as Maintenance
      state "LBM Regression" as Regression
  
      [*] --> Achieved
      Achieved --> Maintenance : Initiate Low-Dose Diazoxide (0.5 mg/kg/day)
      Maintenance --> Maintenance : LBM Stable
      Maintenance --> Regression : If Therapy Ceases
      Achieved --> Regression : If No Maintenance Therapy
  

---

II. Derivatives Based on the Method of Reducing Hyperphagia (Relates to Claim 8)

1. Material & Component Substitution

a. Orexin Receptor Antagonist Co-formulation

• Enabling Description: To create a synergistic effect on hyperphagia, a K-ATP channel opener (diazoxide, 3 mg/kg/day) is co-formulated in a bi-layer tablet with a dual orexin receptor antagonist (DORA), such as suvorexant (10 mg). The K-ATP channel opener provides a baseline metabolic signal of energy sufficiency by inhibiting insulin, while the DORA directly suppresses the hypothalamic "wake and seek food" signals mediated by orexin. This dual-pathway inhibition provides a more profound and sustained reduction in hyperphagia (>25% on the Hyperphagia Questionnaire) than either agent alone.
• Mermaid Diagram:

  graph TD
      subgraph Hypothalamus
          A(Orexin Receptors) -- Blocked by DORA --> B(Reduced Food-Seeking Drive)
      end
      subgraph Pancreas/Metabolism
          C(Pancreatic beta-cells) -- Inhibited by Diazoxide --> D(Reduced Insulin --> Satiety Signal)
      end
      B & D --> E(Synergistic Reduction in Hyperphagia)
      E --> F[PWS Subject];
  

2. Cross-Domain Application

a. Aquaculture: Appetite Control for Optimized Growth Cycles

• Enabling Description: In the farming of carnivorous fish like Atlantic Salmon (Salmo salar), feed is a major cost, and aggressive feeding can lead to waste and poor water quality. This method involves introducing a K-ATP channel opener into the aqueous environment in a controlled, pulsed manner to temporarily suppress appetite. By reducing hyperphagia during specific periods (e.g., post-grading or pre-harvest), farmers can manage growth rates, reduce feed waste, and improve the overall efficiency of the aquaculture operation. The K-ATP opener is cleared from the fish's system well before harvest.
• Mermaid Diagram:

  gantt
      title Salmon Farming Appetite Control
      dateFormat  MM-DD
      section Growth Cycle
      Normal Feeding      : 05-01, 30d
      Appetite Suppression : 06-01, 5d
      Normal Feeding      : 06-06, 30d
      Pre-Harvest Fasting : 07-06, 3d
  

3. Integration with Emerging Tech

a. IoT-Monitored Behavioral Intervention

• Enabling Description: A system combines a low-dose K-ATP channel opener with an IoT-enabled "smart kitchen." Sensors on refrigerators and pantry doors log all food-access events. A wearable wristband monitors physiological signs of agitation often preceding food-seeking behavior in PWS. When the system's AI detects a pattern of hyperphagic behavior (e.g., frequent, agitated access attempts), it triggers an alert to a caregiver's phone and logs the event against the patient's medication schedule. This data is used to titrate the drug dose to the minimum effective level required to control the specific patient's behavioral patterns.
• Mermaid Diagram:

  sequenceDiagram
      participant Patient
      participant SmartKitchenSensors
      participant CaregiverAI
      loop Continuous Monitoring
          Patient->>SmartKitchenSensors: Attempts to access food
          SmartKitchenSensors->>CaregiverAI: Log Access Event (Time, Duration)
          alt Hyperphagic Pattern Detected
              CaregiverAI->>CaregiverAI: Correlate with drug schedule
              CaregiverAI->>CaregiverAI: Recommend dose adjustment
          end
      end
  

---

III. Combination Prior Art with Open-Source Standards

1. AI-Dosing Algorithm with TensorFlow and FHIR

• Enabling Description: A method for personalized treatment of PWS subjects where a predictive model, built using the open-source TensorFlow framework, determines the optimal daily dose of a K-ATP channel opener. The model ingests patient data (genotype, age, weight, LBM, food logs) formatted according to the open FHIR (Fast Healthcare Interoperability Resources) standard. The system's output is a FHIR-compliant MedicationRequest resource, which is transmitted to a pharmacy or clinical management system, ensuring interoperability with existing electronic health records (EHRs). This combination of an open-source AI framework and an open data standard allows for a transparent, reproducible, and integrable clinical decision support tool.

2. Genomic-Stratified Treatment Protocols via ClinVar

• Enabling Description: A method wherein PWS subjects are first stratified based on their specific genetic subtype (e.g., Type I Deletion, Type II Deletion, Uniparental Disomy). This genetic information is retrieved from or cross-referenced with the open-source ClinVar database. A treatment algorithm then selects a specific K-ATP channel opener and starting dose based on published associations in ClinVar between the genetic variant and metabolic phenotype. For example, subjects with subtypes linked to more severe insulin dysregulation might receive a higher initial dose. This creates a data-driven, personalized medicine approach based on public, open-source genomic data.

3. Blockchain-Verified Supply Chain for Combination Therapy

• Enabling Description: A method for ensuring the authenticity and integrity of the combination therapy (K-ATP channel opener and Growth Hormone). The supply chain is managed on a permissioned blockchain platform built using the open-source Hyperledger Fabric framework. Each drug package is assigned a unique, non-fungible token (NFT). Every transaction—from manufacturer to distributor to pharmacy to patient administration—is recorded as an immutable block. Caregivers can scan a QR code on the package to verify its entire provenance on the blockchain, preventing counterfeiting and ensuring that the two critical components of the therapy are authentic and have been properly handled.